

2019 OPA Annual Conference Learning Objectives

ACPE #0129-0000-19-019-L04-P

Parlaying Pearls of Experiential Education

Experiential Education Directors, Ohio Colleges of Pharmacy

At the completion of this activity, the participant will be able to:

1. explain the role entrustable professional activities (EPAs) have in experiential education;
2. define the Pharmacists' Patient Care Process (PPCP);
3. demonstrate how to use the PPCP when precepting students;
4. explain the difference between Continuing Education and Continuing Professional Development;
5. identify when and how to communicate with the office of experiential education; and
6. identify strategies and resources to help students with mental health struggles while on rotations.

ACPE #0129-0000-19-020-L01-P

Piecing Together Insulin Pump Therapy and the Role of a Pharmacist

Melody L. Hartzler, PharmD, BCACP, BC-ADM, Clinical Pharmacist & Chronic Care Coordinator and Samantha Yates, PharmD, PGY1 Community Pharmacy Resident, Western Medicine, Inc.; Kevin Kelleher, BSN, RN, CDE, Sr. Clinical Territory Manager, Medtronic Diabetes

At the completion of this activity, the participant will be able to:

1. review clinical evidence on insulin pump therapy;
2. examine the pharmacodynamics of insulin pump therapy;
3. illustrate Continuous Glucose Monitoring (CGM) clinical practice use and billing opportunities;
4. discuss economic impact of insulin pump therapy vs. standard basal-bolus;
5. explain progression of insulin pump technology; and
6. discuss clinical pearls of insulin pump management and dispensing.

ACPE #0129-0000-19-021-L04-P

Partnering with Ohio's Area Agencies on Aging to Serve Your Older Adult Patients

Julie Trackler, Chief, Elder Connections Division, Ohio Department of Aging; Duana Patton, CEO, Ohio District 5 Area Agency on Aging; Jacquelyn Bradley, Director, Area Agency on Aging 3

At the completion of this activity, the participant will be able to:

1. explain the role of Ohio's Area Agencies on Aging (AAAs) and how the network addresses concerns of older adults;
2. identify the AAA office that services his/her region of the state;
3. describe the resources available to help pharmacists meet patient needs and improve quality of care;
4. identify suspected elder abuse and know how to report it; and
5. discuss how pharmacists and Area Agencies can work as part of an interdisciplinary team to better serve patients.

ACPE #0129-0000-19-022-L01-P

The Journey of Recovery from Addiction

Phyllis A. Grauer, PharmD, BCGP, CPE, CDCA, Charxis Consulting, LLC

At the completion of this activity, the participant will be able to:

1. describe the characteristics of addiction;
2. discuss how addiction affects the addict and their loved ones; and
3. list available support and treatment options for the addict and their family.

ACPE #0129-0000-19-023-L01-P

2019 OTC and Self-Care Challenge

Moderators: Kristine Mason, PharmD, PGY2/MS Community-based Pharmacy Administration and Leadership resident, OSU and Kroger Health & Wellness; and Brianne Porter, PharmD, MS, Assistant Professor – Practice, The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

1. discuss current topics related to nonprescription medications;
2. describe appropriate nonprescription treatment options for common self-care conditions;
3. identify the rationale for the selection of a particular product for a described self-care condition; and
4. identify key counseling points for OTC medications.

ACPE #0129-0000-19-024-L04-P

Future Trends and Technologies in Pharmacy

Adam Chesler, PharmD, Director, Regulatory Affairs, Cardinal Health

At the completion of this activity, the participant will be able to:

1. explain some of the advances in technology and how it is impacting the delivery of services;
2. describe upcoming trends seen in the pharmacy industry and how it might change the practice;
3. recognize possible legal barriers to entry and ramifications of implementation;
4. identify current needs in the healthcare industry and the impact on patients; and
5. discuss the future implications of the safe practice of pharmacy.

ACPE #0129-0000-19-025-L04-P

Ohio Comprehensive Primary Care (CPC): A Value-Based Opportunity for Pharmacists

Stuart Beatty, PharmD, Associate Professor of Clinical Pharmacy, The Ohio State University College of Pharmacy; Marjorie Yano, Payment Innovation Director and Mylynda Drake, Comprehensive Primary Care Program Administrator, Ohio Department of Medicaid; Phillip Farwig, PharmD and Jennifer Sabatino, PharmD, Specialty Practice Pharmacists, The Ohio State University Physicians, Inc.

At the completion of this activity, the participant will be able to:

1. discuss the Ohio Comprehensive Primary Care (CPC) initiative as a value-based payment opportunity for team-based care;
2. describe quality measures, payment structure, and risk stratification used by Ohio CPC practices; and
3. explain how pharmacists can help providers meet Ohio CPC metrics for high-risk, high-cost patient populations.

ACPE #0129-0000-19-026-L01-P

Innovative Approaches to Change Opioid Prescribing Practices and Improve Patient Engagement in Care

Aleda M. H. Chen, PharmD, PhD, Assistant Dean and Associate Professor; Marc Sweeney, PharmD, Dean and Professor; Cedarville University School of Pharmacy

At the completion of this activity, the participant will be able to:

1. summarize the evidence base for chronic pain management and current clinical guidelines;
2. describe potential barriers and solutions to changing opioid prescribing practices;
3. describe potential barriers and solutions to using goal-directed encounters to increase patient engagement in pain management;
4. develop a plan to address barriers in pain management practices; and
5. discuss solutions to barriers in changing pain management practices.

ACPE #0129-0000-19-027-L01-P

Angina Pectoris: Understanding the Heart of the Pain

*Vincent F. Mauro, RPh, PharmD, FCC, Professor of Clinical Pharmacy
The University of Toledo College of Pharmacy and Pharmaceutical Sciences*

At the completion of this activity, the participant will be able to:

1. compare and contrast stable angina, unstable angina, and variant angina;
2. explain the pathogenesis of atherosclerosis;
3. describe the clinical presentation of the three types of angina;
4. summarize the pharmacotherapy of the three types of angina; and
5. choose appropriate pharmacotherapy for selected patient cases.

ACPE #0129-0000-19-028-L04-P

Ohio Research Forum 2019

Moderator: Timothy R. Ulbrich, PharmD, Clinical Professor of Pharmacy and Program Director, MS – Health-System Pharmacy Administration; OSU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. describe research projects being conducted by pharmacists, student pharmacists and faculty in Ohio; and
2. describe the impact these research projects have on the practice of pharmacy, economic/social/administrative areas within the profession and/or pharmacy education.

ACPE #0129-0000-19-029-L01-P

Details on DOACs: Indications, Monitoring, Adherence, and More!

Heather A. Johnson, PharmD; E. Michael Murphy, PharmD; PGY1 Pharmacy Residents, Ambulatory Care, The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

1. match indications and dosing for direct oral anticoagulants(DOACs);
2. recall required laboratory monitoring for DOACs;
3. use findings on adherence to DOACs to impact prescribing and management of patients on DOACs; and
4. identify reversal agents for DOACs.

ACPE #0129-0000-19-030-L04-P

Strategies to Improve Patient Health Through Pharmacist-Provided Care

Micah Cost, PharmD, MS, Executive Director, Tennessee Pharmacists Association

At the completion of this activity, the participant will be able to:

1. discuss recent legislative changes in Tennessee to position pharmacists as medical providers;
2. describe opportunities and challenges related to credentialing and contracting of pharmacists as medical providers;
3. identify opportunities for pharmacists to contribute to the health care team; and
4. outline key stakeholders and strategic partners that can assist in facilitating the credentialing and contracting of pharmacists as medical providers.

ACPE #0129-0000-19-031-L04-P

Ohio Innovative Practice Forum 2019

Moderators: Jennifer Rodis, PharmD, BCPS, FAPhA, Clinical Associate Professor of Pharmacy and Assistant Dean for Outreach and Engagement and Timothy R. Ulbrich, PharmD, Clinical Professor of Pharmacy and Program Director, MS – Health-System Pharmacy Administration; OSU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. describe innovative pharmacy practice models in Ohio;
2. explain how individual pharmacy practices and practitioners are expanding patient care services;
3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
4. apply these ideas, opportunities, and resources to enhance his/her own pharmacy practice.

ACPE #0129-0000-19-032-L04-P

Side Effects: The Story Behind the Story of Ohio's PBM Upheaval

Eric Pachman, MBA, Drug Pricing Researcher, 46brooklyn Research; Darrel Rowland, Public Affairs Editor; Cathy Candisky and Marty Schladen, Public Affairs Reporters; and Lucas Sullivan, Special Projects Reporter, Columbus Dispatch

At the completion of this activity, the participant will be able to:

1. identify PBM drug pricing patterns in the Ohio Medicaid managed care program;
2. explain how to effectively communicate pharmacy issues with lawmakers and media;
3. utilize public drug pricing data to better educate others about drug costs; and
4. recognize the key role that journalists play in holding health care delivery and payment systems accountable.

ACPE #0129-0000-19-033-L01-P

***Clostridium difficile* Infection: Scope of Disease and Updates to Treatment**

Andrew M. Roecker, PharmD, R.Ph., BCPS, Professor and Chair, Department of Pharmacy Practice and Director of Continuing Education, Raabe College of Pharmacy, Ohio Northern University

At the completion of this activity, the participant will be able to:

1. discuss the pathogenesis and risk factors for infections caused by *Clostridium difficile*;
2. describe the guidelines for treatment of *Clostridium difficile* infection (CDI); and
3. explain techniques for prevention of CDI.

ACPE #0129-0000-19-034-L03-P

Pharmacy Law Update 2019

Sheri Zapadka, R.Ph., Compliance Specialist; State of Ohio Board of Pharmacy

At the completion of this activity, the participant will be able to:

1. identify recent changes in state and federal laws and rules which impact pharmacy practice;
2. describe the effect of recent changes in laws and rules on his/her specific practice of pharmacy; and
3. review commonly asked questions about existing pharmacy laws and rules.

ACPE #0129-0000-19-035-L01-P

Approaches to Acute and Chronic Pain in Patients with Addictive Disease

Theodore Parran, Jr., MD, Isabel and Carter Wang Professor and Chair in Medical Education, Case Western Reserve University School of Medicine

At the completion of this activity, the participant will be able to:

1. outline the pharmacologic characteristics of controlled drugs;
2. compare and contrast the substance abusing brain with those without substance abuse; and
3. develop a strategy to assess risk vs. benefit of different pharmacologic approaches to acute and chronic pain management in patients with substance use disorders.

ACPE #0129-0000-19-036-L04-P

An Ounce of Prevention: Pharmacist Provision of Clinical Preventive Services

Natalie DiPietro Mager, PharmD, MPH, Associate Professor of Pharmacy Practice, ONU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. list and describe the clinical preventive services recommended for the general adult population by the U.S. Preventive Services Task Force (USPSTF);
2. explain how USPSTF recommended services can be delivered or referred by pharmacists; and
3. apply USPSTF recommendations for clinical preventive services to patient cases.

ACPE #0129-0000-19-037-L04-P

Outcomes-based Technology – Empowering Pharmacists and Helping Patients

Perry Lewis, Vice President of Industry Relations, CoverMyMeds

At the completion of this activity, the participant will be able to:

1. review the evolving role of pharmacists in patient care through legislation (e.g. vaccination and dispensing laws) and greater prescribing abilities;
2. describe electronic prior authorization (ePA) technology, including recent legislation on ePA, industry-wide integration of ePA, impact of ePA on efficiency relative to traditional PA and value of the prospective ePA workflow;
3. describe real-time benefit check (RTBC), including its synergy with ePA and potential to enhance patient care;
4. review the current specialty process and corresponding burdens to stakeholders;
5. outline the potential impact of ePA and RTBC on the specialty process; and
6. describe the importance of industry standardization of technologies, through efforts of NCPDP, to modernize health care and improve patient care.

ACPE #0129-0000-19-038-L04-P

Leadership Throughout Your Career

Moderator: Jennifer Sabatino, PharmD, R.Ph., BCACP, Clinical Pharmacist at OSU General Internal Medicine; and Panel of Pharmacist Leaders

At the completion of this activity, the participant will be able to:

1. recognize and be prepared for challenges he/she may face as a new practitioner in a leadership role; and
2. identify tools to help him/her succeed as a leader in pharmacy

ACPE #0129-0000-19-039-L01-P

Best Practices in Medication Assisted Opioid Treatment

Theodore Parran, Jr., MD, Isabel and Carter Wang Professor and Chair in Medical Education, CWRU School of Medicine

At the completion of this activity, the participant will be able to:

1. compare and contrast the efficacy of naltrexone, methadone and buprenorphine in the treatment of opioid use disorder;
2. describe harm reduction and adjunct to sobriety approaches in addiction treatment; and
3. list advantages of different formulations of the three major medication assisted treatment (MAT) medications.

ACPE #0129-0000-19-040-L01-P

Implementing Medical Marijuana Education into Existing Patient Centered Care Practices

Jessica Hinson, PharmD, BCACP, NCTTP, Assistant Professor of Pharmacy Practice and Pharmacist, ONU HealthWise Pharmacy; Amber Williams, PharmD Candidate; Ohio Northern University

At the completion of this activity, the participant will be able to:

1. identify how medical marijuana may affect patient engagement and adherence;
2. recognize adverse drug events associated with medical marijuana; and
3. describe resources available for assessing appropriate medication therapy adjunct to medical marijuana use.

ACPE #0129-0000-19-041-L06-P

Immunization Update 2019

Donald L. Bennett, R.Ph., MBA, Clinical Assistant Professor, The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

1. discuss the Centers for Disease Control and Prevention (CDC) identified trends in vaccine-preventable disease prevalence;
2. describe the recent changes in recommendations from the CDC Advisory Committee on Immunizations Practices;
3. discuss the impact of the 2018-2019 influenza season; and
4. explain recent trends in vaccine-related medication errors.

ACPE #0129-0000-19-042-L04-P

Innovative Pharmacy Business Plan Competition 2019

Finalist teams and panel of judges TBA

At the completion of this activity, the participant will be able to:

1. identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
2. explain the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
3. recognize how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

ACPE #0129-0000-19-043-L04-P

Pharmacy Technician Full Scope of Practice: Evidence > Emotions

Deeb D. Eid, PharmD, Assistant Professor/Experiential Coordinator at Ferris State College of Pharmacy

At the completion of this activity, the participant will be able to:

1. identify national landscape data of pharmacy technicians and recognize recent updates or changes in laws and practice models;
2. interpret and consider future applications of “full scope of practice” through legislative, literature, education/training, and historical based data on pharmacy technician roles; and
3. compare and contrast regional and national legislation, practice models, evidence based outcomes, and education/training requirements for pharmacy technicians.

ACPE #0129-0000-19-044-L01-P

Making a Difference for Individuals with Cancer and Their Caregivers

Bethanne Brown, PharmD, BCACP, Associate Professor; Rowena Schwartz, PharmD, BCOP, Associate Professor; Jenelle Sobotka, PharmD, Professor; Winkle College of Pharmacy University of Cincinnati

At the completion of this activity, the participant will be able to:

1. describe the “patient’s experience” from cancer diagnosis to survivorship and the opportunities for pharmacists to provide assistance through that experience;
2. identify available educational resources for the health care professional and patients/caregivers to help navigate treatment, treatment-related toxicities and disease-related complications; and
3. discuss potential opportunities for pharmacists to optimize and facilitate coordination of care across treatment settings.

ACPE #0129-0000-19-045-L05-P

START, STOPP or Beers? How to Move Toward Safe Medication Use in Older Adults

Ruth Emptage, R.Ph., PharmD, BCGP and Zach Woods, R.Ph., PharmD; Assistant Professors – Practice, OSU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. review the impact of published criteria on safe medication use in older adults;
2. describe appropriate use of the START/STOPP criteria by pharmacists;
3. explain appropriate use of the updated Beers Criteria by pharmacists; and
4. apply a patient safety focused approach to comprehensive medication reviews for older adults to eliminate or mitigate patient injury caused by healthcare errors.

ACPE #0129-0000-19-046-L04-P

Optimizing Personal and Organizational Well-Being to Decrease Professional Burnout: An Evidence-based Primer for Pharmacists!

Bernadette Melnyk, PhD, RN, APRN-CNP, FAANP, FNAP, FAAN, Chief Wellness Officer and Vice President for Health Promotion; Dean and Professor, College of Nursing; The Ohio State University

At the completion of this activity, the participant will be able to:

1. discuss key strategies for optimizing their own personal and professional well-being; and
2. describe evidence-based strategies for building and sustaining wellness cultures in organizations that yield positive return on investment and value of investment.

ACPE #0129-0000-19-047-L01-P

Pharmacogenomics: An Introduction to an Opportunity

Sue Paul, R.Ph., Founder SyneRxgy Consulting, Co-Founder PGx101 and Medipreneurs; Daniel Krinsky BS, MS, R.Ph., Professor, Department of Pharmacy Practice, NEOMED and Co-Founder PGx101; Amy Van Milligan, MD, Crossroad Health Center

At the completion of this activity, the participant will be able to:

1. define general terms related to pharmacogenomics;
2. discuss ways that pharmacogenomics (PGx) and pharmacokinetics (PK) can improve prescribing and outcomes;
3. describe at least two resources that pharmacists might use to answer questions specific to PGx or PK;
4. describe challenges and opportunities with PGx testing; and
5. apply basic PGx information to example case studies.

ACPE #0129-0000-19-048-L01-P

The Role of LDL Targets in the Updated ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol

Patricia Wigle, BCPS, BCACP, FCCP, Professor, Division of Pharmacy Practice and Administrative Sciences, UC College of Pharmacy

At the completion of this activity, the participant will be able to:

1. define patients who are classified as very high-risk ASCVD;
2. discuss evidence supporting LDL-C level goals in patients with very high-risk ASCVD; and
3. compare and contrast cholesterol management for patients with clinical ASCVD and very high-risk ASCVD.

ACPE #0129-0000-19-049-L01-P

New Drug Update 2019

Karen Kier, PhD, M.Sc., R.Ph., Professor of Clinical Pharmacy, Director of Assessment, ONU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. describe the pharmacology and therapeutics of the drugs presented that were released to market within the past year;
2. state the indications and clinical applications of the medications presented;
3. identify the most common adverse effects, toxicities, and significant drug-drug interactions reported with these medications; and
4. explain important patient counseling information on these medications.

ACPE #0129-0000-19-050-L04-P

Legislative Update 2019

Ernest Boyd, PharmD (Hon), CAE, and Antonio Ciaccia, OPA Lobbyists

At the completion of this activity, the participant will be able to:

1. describe recent legislative and regulatory changes that impact the practice of pharmacy;
2. explain the progress of pending and future advocacy initiatives, including PBM reform and further expansion of pharmacist services; and
3. discuss OPA's legislative agenda for 2019 and what it may mean for pharmacy practice.

ACPE #0129-0000-19-051-L01-P

Diabetes in 2019: What's New and on the Horizon?

Diana Isaacs, PharmD, BCPS, BC-ADM, CDE, Clinical Pharmacy Specialist and CGM Program Coordinator, Cleveland Clinic Endocrinology & Metabolism Institute Diabetes Center

At the completion of this activity, the participant will be able to:

1. summarize guideline updates from the American Diabetes Association and the American Association of Clinical Endocrinologists;
2. describe new agents in the pipeline for type 1 and type 2 diabetes;
3. compare and contrast new diabetes medications and formulations to what was previously available; and
4. outline when to use new medications for specific patient populations.

ACPE #0129-0000-19-052-L01-P

Dispensing Naloxone 101: Get in Your Comfort Zone

Dana Wilkerson, PharmD, MS, System Ambulatory Pharmacy Manager, Pharmacy Systems Inc./Holzer Health System; Bella Mehta, PharmD, FAPhA, Professor of Clinical Pharmacy & Family Medicine, OSU College of Pharmacy; Kristine Mason, PharmD, PGY2/MS Community-based Pharmacy Administration and Leadership resident, OSU and Kroger Health & Wellness

At the completion of this activity, the participant will be able to:

1. describe the role of pharmacists and pharmacy interns in dispensing naloxone without a prescription in community-based pharmacies in Ohio;
2. report research findings related to pharmacists' and pharmacy interns' knowledge and comfort with dispensing naloxone without a prescription; and
3. develop an appropriate counseling and monitoring plan for dispensing naloxone without a prescription for given patient case scenarios.

ACPE #0129-0000-19-053-L01-P

A Functional Medicine Approach to Dietary Supplements and Nutrition

Lauren Castle, PharmD, MS; Founder, Functional Medicine Pharmacists Alliance

At the completion of this activity, the participant will be able to:

1. compare and contrast the definitions of dietary supplements, functional foods, medical foods, nutraceuticals, and nutrition vs. diet;
2. review the most common uses, safety, efficacy, and mechanisms of action of popular dietary supplements; and
3. explain the utility of dietary supplements and foods found in the OTC aisle for use in popular diets such as Mediterranean, Paleolithic, ketogenic, and vegan diets while maintaining scope of practice laws.